NeurogesX and Astellas Pharma entered into an exclusive distributive, marketing and licensing agreement for the commercialisation of Qutenza™ (capsaicin) in Europe, Middle East and Africa. The deal hooks an upfront of US$49 M for the pain therapy. Qutenza is expected to be launched in Europe in the first half of 2010.